
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Phil Challis, vice-president of product development at eTheRNA, discusses four of the major challenges in working with mRNA therapeutics.
Phil Challis, vice-president of product development at eTheRNA, discusses four of the major challenges in working with mRNA therapeutics. Some topics he touches on include; what makes a good RNA construct; making RNA more tolerable; storage and distribution of lipid nanoparticles; and more.
For more INTERPHEX 2023 video content, check






